Worth reading
59In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Mixed performance
Direction inferred from the company’s description.Scale
—
Displayed only when the document provides numerical figures.Wording
Definitive
How definitive the wording is.Who is moving to which position
Resolved 16 July 2026Incoming appointee
3 itemsScheduled Appointment Date18 December 2026 (subject to approval at the annual general meeting of shareholders) and 1 October 2026 (executive officers)
Matsui Yukio (松井幸郎)
Previous positionOutside Director of MANI,INC. (currently serving), Operating Advisor, Goldman Sachs Asset Management Value Accelerator (currently serving), and Advisor to TOHO HOLDINGS CO.,LTD. (currently serving)
New positionDirector (Independent)
Chaudhary Kushendra
Previous positionNot disclosed
New positionExecutive Officer, Head of Business Development Department
Okuda Mariko (奥田真理子)
Previous positionNot disclosed
New positionExecutive Officer, Head of Human Resources and Governance Promotion Department
Date of birthMatsui Yukio (松井幸郎): born 24 January 1961; Chaudhary Kushendra: Not disclosed; Okuda Mariko (奥田真理子): Not disclosed
Year joined the companyMatsui Yukio (松井幸郎): no prior employment with the Company; Chaudhary Kushendra: Not disclosed; Okuda Mariko (奥田真理子): Not disclosed
Because the names and counts do not correspond, they are shown as reported without linking the counts to individual names.Departing officer
2 itemsDate of departure18 December 2026
Kamide Toyoyuki (上出豊幸)Stepping down
Hirai Keiji (平井敬二)Stepping down
New positionRetirement
Because the names and counts do not correspond, they are shown as reported without linking the counts to individual names.Whether the incumbent will remain in office (whether they will retain their position)
Will not remain on the Board of Directors
Directors after the change8Number
Shareholders’ meeting approvalRequired. A proposal for the election of the director nominees will be submitted to the annual general meeting of shareholders scheduled for 18 December 2026.
Reason for change
To welcome a new outside director and leverage extensive experience in the global pharmaceutical industry to advance the Company's growth strategy and enhance corporate value over the medium to long term
Reasons for appointment
Matsui Yukio (松井幸郎) was engaged in domestic and international pharmaceutical businesses at Astellas Pharma Inc. for approximately 40 years, serving in key positions including Chief Commercial Officer and Head of the European Business. He has extensive experience and deep insight into global business operations, management strategy, marketing and organisational transformation, and is currently involved in enhancing corporate governance as an outside director of a listed company.
| Item | Details |
|---|---|
| Resolution date | 16 July 2026 |
| Scheduled Appointment Date | 18 December 2026 (subject to approval at the annual general meeting of shareholders) and 1 October 2026 (executive officers) |
| Date of departure | 18 December 2026 |
| Name of appointee | Matsui Yukio (松井幸郎), Chaudhary Kushendra, Okuda Mariko (奥田真理子) |
| Appointee's new position | Director (Independent), Executive Officer, Head of Business Development Department, Executive Officer, Head of Human Resources and Governance Promotion Department |
| Appointee's previous position | Outside Director of MANI,INC. (currently serving), Operating Advisor, Goldman Sachs Asset Management Value Accelerator (currently serving), and Advisor to TOHO HOLDINGS CO.,LTD. (currently serving), Not disclosed, Not disclosed |
| Appointee's date of birth | Matsui Yukio (松井幸郎): born 24 January 1961; Chaudhary Kushendra: Not disclosed; Okuda Mariko (奥田真理子): Not disclosed |
| Year the appointee joined the Company | Matsui Yukio (松井幸郎): no prior employment with the Company; Chaudhary Kushendra: Not disclosed; Okuda Mariko (奥田真理子): Not disclosed |
| Name of departing officer | Kamide Toyoyuki (上出豊幸), Hirai Keiji (平井敬二) |
| New position of departing officer | Retirement |
| Whether the incumbent will remain in office | Will not remain on the Board of Directors |
| Reason for change | To welcome a new outside director and leverage extensive experience in the global pharmaceutical industry to advance the Company's growth strategy and enhance corporate value over the medium to long term |
| Reasons for appointment | Matsui Yukio (松井幸郎) was engaged in domestic and international pharmaceutical businesses at Astellas Pharma Inc. for approximately 40 years, serving in key positions including Chief Commercial Officer and Head of the European Business. He has extensive experience and deep insight into global business operations, management strategy, marketing and organisational transformation, and is currently involved in enhancing corporate governance as an outside director of a listed company. |
| Number of directors after the change | 8 directors, including 4 independent outside directors |
| Subject to Approval by the General Meeting of Shareholders | Required. A proposal for the election of the director nominees will be submitted to the annual general meeting of shareholders scheduled for 18 December 2026. |
Items this document does not state (6)
Number of shares held by the appointeeFormer position of departing officerReason for departureFiling as an independent officerDetails of organizational changesChange in Corporate Governance Structure
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To leverage the extensive global pharmaceutical industry experience of the new outside director in advancing the growth strategy and enhancing corporate value over the medium to long term. In the case of Matsui Yukio (松井幸郎), to apply his experience and knowledge in global business operations, management strategy, marketing, organisational transformation and corporate governance to the Company's management.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.